Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure

Nephrology Dialysis Transplantation

Volumn 31, Issue 5, 2016, Pages 767-772

  Andersen, Ingrid A ^a   Huntley, Brenda K ^a   Sandberg, Sharon S ^a   Heublein, Denise M ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

biomarkers FGF23gene expression; GFR; heart failure; myocardium

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FIBROBLAST GROWTH FACTOR;

ACUTE HEART FAILURE; ADULT; AGE; AGED; ARTICLE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ACUTE DISEASE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; HEART FAILURE; METABOLISM; MIDDLE AGED;

ACUTE DISEASE; AGED; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN;

EID: 84965145976     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv398     Document Type: Article

References (21)

1. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435
2. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505
3. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112: 683-692
4. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277: 494-498
5. Saji F, Shiizaki K, Shimada S et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 2009; 111: p59-p66
6. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
7. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922
8. Fliser D, Kollerits B, NeyerUet al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
9. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
10. Arnlov J, CarlssonAC, Sundstrom J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83: 160-166
11. Gruson D, Lepoutre T, Ketelslegers JM et al. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012; 37: 258-262
12. PlischkeM, Neuhold S, Adlbrecht C et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest 2012; 42: 649-656
13. Richter M, Polyakova V, Gajawada P et al. Oncostatin M induces FGF23 expression in cardiomyocytes. J Clin Exp Cardiolog 2012; doi:10.4172/2155-9880.S4179-4003
14. van Venrooij NA, Pereira RC, Tintut Y et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant 2014; 29: 1525-1532
15. Moe SM, Chertow GM, Parfrey PS et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015; 132: 27-39
16. Poss J, Mahfoud F, Seiler S et al. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2013; 2: 211-218
17. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
18. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-551
19. Semba RD, Cappola AR, Sun K et al. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc 2011; 59: 1596-1601
20. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553
21. Quarles LD. Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new. J Clin Invest 2013; 123: 542-543